Verona Pharma (VRNA) versus Its Peers Financial Review
Verona Pharma (NASDAQ: VRNA) is one of 487 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Verona Pharma to similar businesses based on the strength of its dividends, analyst recommendations, valuation, profitability, risk, earnings and institutional ownership.
Institutional and Insider Ownership
50.9% of Verona Pharma shares are held by institutional investors. Comparatively, 47.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.1% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a summary of current recommendations and price targets for Verona Pharma and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Verona Pharma Competitors||2966||9011||21910||616||2.58|
Verona Pharma currently has a consensus price target of $34.60, indicating a potential upside of 105.71%. As a group, “Pharmaceutical preparations” companies have a potential upside of 39.28%. Given Verona Pharma’s stronger consensus rating and higher probable upside, research analysts plainly believe Verona Pharma is more favorable than its rivals.
This table compares Verona Pharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Verona Pharma Competitors||-2,956.21%||-162.38%||-29.64%|
Earnings and Valuation
This table compares Verona Pharma and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Verona Pharma||N/A||-$26.41 million||-6.98|
|Verona Pharma Competitors||$2.02 billion||$137.46 million||-3.69|
Verona Pharma’s rivals have higher revenue and earnings than Verona Pharma. Verona Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
About Verona Pharma
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.